Mustafa YILDIRIM, Melih Engin ERKAN, Muhammet AŞIK, Taner UÇGUN, Ayşe YILMAZ, Huri Tilla İLÇE, Yusuf ASLANTAŞ, Ramazan MEMİŞOĞULLARI, Serkan BULUR, Ahmet Semih DOĞAN

Resistin predicts ischemia in myocardial perfusion scintigraphy

Resistin plays a role in the pathogenesis of coronary artery disease and is related to mortality and morbidity through a number of mechanisms. We hypothesize that plasma resistin levels are increased in the presence of ischemia, as measured by GATED single-photon emission computed tomography myocardial perfusion scintigraphy (SPECT MPS), in comparison with nonischemic subjects. Materials and methods: Fasting intravenous blood samples of patients were drawn before a stress test. An ELISA kit was used for the assays. All patients underwent a technetium 99m-sestamibi GATED SPECT MPS study with a 1-day stress-rest protocol. Images were analyzed visually and patients were assessed as ischemic or nonischemic. Resistin levels were presented as medians (25th-75th percentiles) and were compared using the Mann-Whitney U test. Results: Plasma resistin levels were higher in the ischemic group (n = 47) than in the nonischemic group (n = 67) [9.04 umol/L (6.27-11.8 umol/L) vs. 3.56 umol/L (0.39-7.93 umol/L), respectively; P < 0.001). We showed that plasma resistin levels (OR = 1.26, 95% CI: 1.13-1.41; P < 0.001) and METs (OR = 0.82, 95% CI: 0.70-0.92; P = 0.021) were independent predictors of ischemia. No linear correlation was found between plasma resistin levels and GATED SPECT or stress test parameters. Conclusion: Increased baseline resistin levels are independently related to presence of ischemia but are not related to the extent or severity of ischemia, or other functional parameters such as poststress ejection fraction, end systolic, and end diastolic volumes.

Anahtar Kelimeler:

Key words: Resistin, myocardial perfusion scintigraphy, ischemia

Resistin predicts ischemia in myocardial perfusion scintigraphy

Keywords:

Key words: Resistin, myocardial perfusion scintigraphy, ischemia,

PDF

___

On YK, Park HK, Hyon MS, Jeon ES. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007; 71: 868–73.
Al-Daghri N, Chetty R, McTernan PG, Al-Rubean K, Al- Attas O, Jones AF, Kumar S. Serum resistin is associated with C-reactive protein & LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 2005; 4: 10.
Zhang MH, Na B, Schiller NB, Whooley MA. Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. Atherosclerosis 2010; 213: 604–10
Yaseen F, Jaleel A, Aftab J, Zuberi A, Alam E. Circulating levels of resistin, IL-6 and lipid profile in elderly patients with ischemic heart disease with and without diabetes. Biomark Med 2012; 6: 97–102.
Kręcki R, Krzemińska-Pakuła M, Drożdż J, Szcześniak P, Peruga JZ, Lipiec P, Orszulak-Michalak D, Kasprzak JD. Relationship of serum angiogenin, adiponectin and resistin levels with biochemical risk factors and the angiographic severity of three- vessel coronary disease. Cardiol J 2010; 17: 599–606.
Pilz S, Weihrauch G, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, März W. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxf) 2007; 66: 380–6
Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, Aczél S, Berchtold S, Drexel H. Relationship between the adipose- tissue hormone resistin and coronary artery disease. Clin Chim Acta 2007; 386: 1–6.
On YK, Park HK, Hyon MS, Jeon ES. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007; 71: 868–73.
Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M, Nakamura H, Ohsuzu F. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005 19; 46: 379– 80.